Knoll Capital Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Knoll Capital Management’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-510	Closed	-$306K	–	20
2016 Q4	$306K	Sell	510 -3	-0.6%	-$3.17K	0.54%	15
2016 Q3	$568K	Hold	513	–	–	1%	15
2016 Q2	$562K	Hold	513	–	–	0.18%	14
2016 Q1	$658K	Hold	513	–	–	0.27%	14
2015 Q4	$1.26M	Hold	513	–	–	0.47%	12
2015 Q3	$566K	Hold	513	–	–	0.24%	14
2015 Q2	$515K	Hold	513	–	–	0.17%	16
2015 Q1	$521K	Buy	+513	New	+$1.69M	0.15%	14

Other funds holding NBSE

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bailard Foster City, California $4.35B AUM 23.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

GBA

Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return

Knoll Capital Management's NBSE Position: Q1 2017 in Review

Knoll Capital Management sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q1 2017, closing a stake of 510 shares — an estimated $306K sold.

Knoll Capital Management first reported a position in NBSE in Q1 2015 and held it in 8 quarters. The position peaked at $1.26M in Q4 2015. 40 funds tracked by Wall St. Rank hold NBSE as of Q1 2017.

Knoll Capital Management reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
Knoll Capital Management sold 510 NeuBase Therapeutics, Inc. Common Stock shares in Q1 2017, an estimated $306K.
Knoll Capital Management first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2015 and held it in 8 quarters.
Knoll Capital Management's NeuBase Therapeutics, Inc. Common Stock position peaked at $1.26M in Q4 2015.
40 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q1 2017.

Based on Knoll Capital Management's 13F filing for Q1 2017, filed 15 May 2017.